Wire · opportunities
FDA Grants SOTIO's SOT106 ADC Orphan Drug and Fast Track Designations for Sarcoma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
The FDA granted SOTIO Biotech's SOT106 antibody-drug conjugate both Orphan Drug and Fast Track Designations for soft tissue sarcoma and osteosarcoma, supporting expedited development and regulatory engagement. SOT106 targets LRRC15 and is expected to start first-in-human trials later in 2026.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 23 Sep 2026 and 24 Sep 2026.
◆ ◆ The Wire takeaway
You now have a faster route to bring sarcoma treatments to market with FDA designations cutting development time and boosting regulatory support. If you are developing oncology ADCs, this opens doors to resource and attention allocation for rare cancers.
◆ Coverage
2 sources · first reported 23 Sep 2026 · latest 24 Sep 2026
◆ Related on Wire
◆ Topics